Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.
et al., 2023, Call for prospective studies of continuous glucose monitoring to define the glycaemic response to bariatric surgery, The Lancet Diabetes & Endocrinology, Vol:11, ISSN:2213-8587, Pages:712-714
et al., 2023, Non-alcoholic fatty liver disease in women – current knowledge and emerging concepts, Jhep Reports, Vol:5, ISSN:2589-5559
et al., 2023, GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification, Nature Genetics, Vol:55, ISSN:1061-4036, Pages:1448-1461
et al., 2023, The postprandial secretion of peptide YY<sub>1-36</sub> and <sub>3-36</sub> in obesity is differentially increased after gastric bypass versus sleeve gastrectomy, Clinical Endocrinology, Vol:99, ISSN:0300-0664, Pages:272-284
et al., 2023, EMBIO trial study protocol: left gastric artery embolisation for weight loss in patients living with obesity with a BMI 35-50 kg/m<SUP>2</SUP>, Bmj Open, Vol:13, ISSN:2044-6055